Alaunos Therapeutics, Inc.

TCRT · Nasdaq · SIC 2834: Pharmaceutical Preparations
419
SEC Filings

Business Summary

Alaunos Therapeutics, Inc. is a preclinical-stage biopharmaceutical company developing novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, including MASLD (fatty liver disease). Its lead candidate, ALN1003, uses a non-hormonal, non-incretin mechanism of action. The company previously developed adoptive TCR-T cell therapies for oncology. It has not generated product revenue and reported a net loss of $4.2 million for the year ended December 31, 2025, with an accumulated deficit of $924.6 million.

Next Earnings

Q2 FY2026 — expected 2026-08-14

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionTCRTdiscussed_in_filing Blockchain & Crypto
topic_mentionTCRTdiscussed_in_filing Healthcare & Bio
topic_mentionTCRTdiscussed_in_filing Blockchain & Crypto
topic_mentionTCRTdiscussed_in_filing Healthcare & Bio
topic_mentionTCRTdiscussed_in_filing Blockchain & Crypto
topic_mentionTCRTdiscussed_in_filing Healthcare & Bio
topic_mentionTCRTdiscussed_in_filing Blockchain & Crypto
topic_mentionTCRTdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-312025-12-310001193125-26-134720EDGAR47K words
2025-03-312024-12-310000950170-25-047758EDGAR—
2024-04-012023-12-310000950170-24-038868EDGAR—
2023-03-072022-12-310000950170-23-006377EDGAR—
2022-03-302021-12-310000950170-22-004972EDGAR—
2021-03-012020-12-310001193125-21-063387EDGAR—
2020-03-022019-12-310001193125-20-058863EDGAR—
2019-03-052018-12-310001193125-19-063978EDGAR—
2018-03-012017-12-310001193125-18-067077EDGAR—
2017-02-162016-12-310001193125-17-046668EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-142025-09-300001193125-25-282988EDGAR18K words
2025-08-142025-06-300000950170-25-108887EDGAR—
2025-05-152025-03-310000950170-25-072709EDGAR—
2024-11-142024-09-300000950170-24-126793EDGAR—
2024-08-142024-06-300000950170-24-097142EDGAR—
2024-05-152024-03-310000950170-24-060075EDGAR—
2023-11-142023-09-300000950170-23-063354EDGAR—
2023-08-142023-06-300000950170-23-042486EDGAR—
2023-05-102023-03-310000950170-23-020088EDGAR—
2022-11-142022-09-300000950170-22-024695EDGAR—
2022-08-152022-06-300000950170-22-017225EDGAR—
2022-05-162022-03-310000950170-22-009942EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-020001193125-26-084084EDGAR1K words
2026-01-080001193125-26-007054EDGAR—
2025-12-230001193125-25-331147EDGAR—
2025-08-200000950170-25-110484EDGAR—
2025-07-220000950170-25-097591EDGAR—
2025-07-170000950170-25-096656EDGAR—
2025-07-100000950170-25-095029EDGAR—
2025-07-020000950170-25-093263EDGAR—
2025-06-260000950170-25-090202EDGAR—
2025-06-260000950170-25-090201EDGAR—

419 total filings indexed. 387 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

obesity-therapeutics metabolic-disorders fatty-liver-disease-(masld) oncology-cell-therapy-(legacy)

Company Identity

CIK0001107421
TickerTCRT
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 9ce9b5eb7cf244cb63614dba48b96950f00884dbe5becb9d7be86fdb72e1df7c
parent: 489869b369835c36b235ebedb2544878c417a3c73269d7a0df23e4866f5b892e
content hash: 99a6c08bc44c1556ba1cb34e755d14364064cecf8037ec4bdbd0137ee7f62945
signed: 2026-04-13T04:47:44.719Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf